Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

434

Participants

Timeline

Start Date

December 26, 2018

Primary Completion Date

June 7, 2023

Study Completion Date

July 10, 2023

Conditions
Growth Hormone Deficiency
Interventions
DRUG

Y-shape pegylated somatropin

Y-shape pegylated somatropin 100μg/kg, subcutaneous injection, Once weekly.

DRUG

Y-shape pegylated somatropin

Y-shape pegylated somatropin 120μg/kg, subcutaneous injection, Once weekly.

DRUG

Y-shape pegylated somatropin

Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.

DRUG

Norditropin®

Norditropin 245μg/kg/week, subcutaneous injection, Once daily.

DRUG

Y-shape pegylated somatropin

Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.

DRUG

Norditropin

Norditropin 245μg/kg/week, subcutaneous injection, Once daily.

Trial Locations (1)

Unknown

Tongji Hospital, Tongji Medical College of HUST, Wuhan

All Listed Sponsors
collaborator

Tongji Hospital

OTHER

lead

Xiamen Amoytop Biotech Co., Ltd.

INDUSTRY